ASTRAZENECA WKN: 886455 ISIN: GB0009895292 Kürzel: AZN Forum: Aktien Thema: Hauptdiskussion

Für mich ist sowas Kindesmord und die Biontech CEO's sollte man umgehend einsperren, ist ja nicht das erste Mal😡😡und wohl auch nicht das letzte Mal:https://www.infranken.de/ueberregional/deutschland/12-jaegriges-kind-nach-corona-impfung-gestorben-art-5327839

Ich schreibe hier nur 🤣🤣🤣

Komisch das hier keiner schreibt 🤔 die Aktie steigt und steigt 👍

25 October 2021 Positive high-level results from the TOPAZ-1 Phase III trial showed Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC).

I love this Stock 🥰

Was aber Umsätze bringen wird - das Antikörpermedikament gegen Covid. Phase 3 Ergebnisse waren Top. Bald muss auch Zulassung kommen

Und Astrazeneca macht fast keine Umsätze mit der Impfung - wird fast für Selbskostenpreis verkauft

Novavax ist nicht tot

Was für eine Impfung sollte Novavax eigentlich produzieren? Kann es sein, dass der "Tod" von Novavax als Versorger für die dritte Welt für AZN doch substantielle Umsätze mit der C Impfung bringen könnte?

15 October 2021 Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localised treatment. This novel dose and schedule of tremelimumab, an anti-CTLA4 antibody, and Imfinzi is called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab). The combination demonstrated a favourable safety profile, and the addition of tremelimumab to Imfinzi did not increase severe hepatic toxicity.

https://www.boersennews.de/nachrichten/artikel/eu-arzneimittelbehoerde-prueft-neues-corona-medikament/3258266/

8 October 2021 Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE).

5 October 2021 AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19.

4 October 2021 The Food and Drug Administration (FDA) has granted Enhertu (trastuzumab deruxtecan), Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. Enhertu is a HER2-directed antibody drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)

29 September 2021 AstraZeneca’s Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb) for the treatment of light chain (AL) amyloidosis.

28 September 2021 AstraZeneca’s Saphnelo (anifrolumab) has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus (SLE), a serious autoimmune disease, who show insufficient response to currently available treatment.